Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer

• Patients (men and women) diagnosed with breast cancer stages I-III initiating first line adjuvant or neoadjuvant therapy with paclitaxel or docetaxel

• Ability to understand and the willingness to sign a written informed consent document.

• Patients with functional limitations due to musculoskeletal conditions can be included, because these conditions are known to remain stable over the relatively short duration of the study.

• Concurrent standard and investigational agents are permissible with the standard chemotherapy drugs.